Ongoing pharmaceutical reforms in France: implications for key stakeholder groups.

[1]  S. Simoens,et al.  Does the Market Share of Generic Medicines Influence the Price Level? , 2011, PharmacoEconomics.

[2]  A. Haycox,et al.  Influence of patient co-payments on atypical antipsychotic choice in Poland , 2011, Applied health economics and health policy.

[3]  A. Haycox,et al.  Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance , 2009, Expert review of pharmacoeconomics & outcomes research.

[4]  A. Wollny,et al.  Reducing unnecessary prescriptions of antibiotics for acute cough: Adaptation of a leaflet aimed at Turkish immigrants in Germany , 2008, BMC family practice.

[5]  A. So,et al.  Meeting the challenge of antibiotic resistance , 2008, BMJ : British Medical Journal.

[6]  Bernard Rachet,et al.  Cancer survival in five continents: a worldwide population-based study (CONCORD). , 2008, The Lancet. Oncology.

[7]  A. Haycox,et al.  Insight into recent reforms and initiatives in Austria: implications for key stakeholders , 2008, Expert review of pharmacoeconomics & outcomes research.

[8]  E. Emanuel,et al.  Tier 4 drugs and the fraying of the social compact. , 2008, The New England journal of medicine.

[9]  S. Simoens.  Trends in generic prescribing and dispensing in Europe , 2008, Expert review of clinical pharmacology.

[10]  O. Kusnik-Joinville,et al.  Prevalence and treatment of diabetes in France: trends between 2000 and 2005. , 2008, Diabetes & metabolism.

[11]  J. Burgerhof,et al.  Determinants of self-medication with antibiotics in Europe: the impact of beliefs, country wealth and the healthcare system. , 2008, The Journal of antimicrobial chemotherapy.

[12]  N. Motterlini,et al.  Prices and distribution margins of in-patent drugs in pharmacy: a comparison in seven European countries. , 2008, Health policy.

[13]  A. Mason,et al.  New medicines in primary care: a review of influences on general practitioner prescribing , 2008, Journal of clinical pharmacy and therapeutics.

[14]  L. Degos,et al.  Can France keep its patients happy? , 2008, BMJ : British Medical Journal.

[15]  A. O'dowd.  Doctors’ leaders partly to blame for recruitment chaos, MPs told , 2007, BMJ : British Medical Journal.

[16]  R. Hopstaken,et al.  Public beliefs on antibiotics and respiratory tract infections: an internet-based questionnaire study. , 2007, The British journal of general practice : the journal of the Royal College of General Practitioners.

[17]  M. Dougados,et al.  Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis. , 2007, Joint, bone, spine : revue du rhumatisme.

[18]  M. Boissier,et al.  TNFalpha antagonists in rheumatoid arthritis patients seen in everyday practice. , 2007, Joint, bone, spine : revue du rhumatisme.

[19]  S. Garattini,et al.  How can we regulate medicines better? , 2007, BMJ : British Medical Journal.

[20]  David G. Taylor,et al.  Pharmacy discounts on generic medicines in France: is there room for further efficiency savings? , 2007, Current medical research and opinion.

[21]  Anders Sundström,et al.  The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months , 2007, Pharmacoepidemiology and drug safety.

[22]  J. Darelid,et al.  Reduction of Antibiotics Sales and Sustained Low Incidence of Bacterial Resistance: Report on a Broad Approach During 10 Years to Implement Evidence‐based Indications for Antibiotic Prescribing in Jönköping County, Sweden , 2007, Quality management in health care.

[23]  E. Poluzzi,et al.  An update on the first decade of the European centralized procedure: how many innovative drugs? , 2006, British journal of clinical pharmacology.

[24]  L. Garattini,et al.  Off-patent drugs in Italy , 2006, The European Journal of Health Economics.

[25]  L. Klareskog,et al.  Swedish registers to examine drug safety and clinical issues in RA , 2006, Annals of the rheumatic diseases.

[26]  S. Straus,et al.  Interventions to improve antibiotic prescribing practices in ambulatory care. , 2005, The Cochrane database of systematic reviews.

[27]  Elias Mossialos,et al.  An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. , 2005, The International journal of health planning and management.

[28]  V. Paris.  Pharmaceutical regulation in France 1980-2003. , 2005, The International journal of health planning and management.

[29]  F. De Ponti,et al.  Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003. , 2005, British journal of clinical pharmacology.

[30]  L. Rochaix,et al.  State autonomy, policy paralysis: paradoxes of institutions and culture in the French health care system. , 2005, Journal of health politics, policy and law.

[31]  Jaume Puig-Junoy,et al.  Incentives and pharmaceutical reimbursement reforms in Spain. , 2004, Health policy.

[32]  B. Allenet,et al.  Opinion and behaviour of pharmacists towards the substitution of branded drugs by generic drugs: survey of 1,000 French community pharmacists , 2003, Pharmacy World and Science.

[33]  C. Pen.  The Drug Budget Silo Mentality: The French Case , 2003 .

[34]  P. Ravaud,et al.  Despite financial penalties, French physicians' knowledge of regulatory practice guidelines is poor. , 2000, Archives of family medicine.

[35]  P. Ihle,et al.  Pharmacotherapeutic Circles , 1999, PharmacoEconomics.

[36]  A. Haycox,et al.  Having Your Cake and Eating It , 2012, PharmacoEconomics.

[37]  A. Haycox,et al.  Recent National and Regional Drug Reforms in Sweden , 2012, PharmacoEconomics.

[38]  B. Wettermark,et al.  Update of Recent Reforms in Germany to Enhance the Quality and Efficiency of Prescribing of Proton Pump Inhibitors and Lipid-Lowering Drugs , 2012, PharmacoEconomics.

[39]  G. Fattore,et al.  The Last Decade of Italian Pharmaceutical Policy , 2012, PharmacoEconomics.

[40]  K. Hassell,et al.  Affordability of medicines and patients’ cost-reducing behaviour , 2005, Applied health economics and health policy.

[41]  L. Nguyen-Kim.  The politics of drug reimbursement in England, France and Germany , 2005 .

[42]  M. Drummond,et al.  Prescribing incentive schemes , 2005, Applied health economics and health policy.

[43]  A. Brouard,et al.  Les autorisations temporaires d'utilisation (ATU) : 50 ans d'histoire de l'évolution de la réglementation des médicaments en France , 2004 .